Ustekinumab: a novel therapeutic option in Crohn's disease

E G Simon; Subrata Ghosh; G W Moran

doi:10.1080/14712598.2016.1205582

Ustekinumab: a novel therapeutic option in Crohn's disease

E G Simon, Subrata Ghosh, G W Moran

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

INTRODUCTION: Although anti-tumour necrosis factor (TNF) agents have caused a paradigm shift in the management of moderate-to-severe Crohn's, they are sometimes associated with diminished or absent response in a considerable proportion of patients. Hence agents targeting pathways other than TNF are needed. Ustekinumab is a monoclonal antibody directed against the p40 subunit of IL-12 and 23.

AREAS COVERED: This manuscript summarises the available evidence on the efficacy and safety of Ustekinumab in Crohn's disease through data available from randomised controlled trials and compassionate use programs across the world.

EXPERT OPINION: Current literature strongly supports the fact that ustekinumab is clinically efficacious and reasonably safe for induction and maintenance of remission in moderate-to-severe Crohn's disease.

Original language	English
Pages (from-to)	1065-74
Number of pages	10
Journal	Expert Opinion in Biological Therapy
Volume	16
Issue number	8
Early online date	6 Jul 2016
DOIs	https://doi.org/10.1080/14712598.2016.1205582
Publication status	Published - Aug 2016

Keywords

Journal Article

Access to Document

10.1080/14712598.2016.1205582

Cite this

@article{d0e21303e7614a90b4ae8f55a58593ed,

title = "Ustekinumab: a novel therapeutic option in Crohn's disease",

abstract = "INTRODUCTION: Although anti-tumour necrosis factor (TNF) agents have caused a paradigm shift in the management of moderate-to-severe Crohn's, they are sometimes associated with diminished or absent response in a considerable proportion of patients. Hence agents targeting pathways other than TNF are needed. Ustekinumab is a monoclonal antibody directed against the p40 subunit of IL-12 and 23.AREAS COVERED: This manuscript summarises the available evidence on the efficacy and safety of Ustekinumab in Crohn's disease through data available from randomised controlled trials and compassionate use programs across the world.EXPERT OPINION: Current literature strongly supports the fact that ustekinumab is clinically efficacious and reasonably safe for induction and maintenance of remission in moderate-to-severe Crohn's disease.",

keywords = "Journal Article",

author = "Simon, {E G} and Subrata Ghosh and Moran, {G W}",

year = "2016",

month = aug,

doi = "10.1080/14712598.2016.1205582",

language = "English",

volume = "16",

pages = "1065--74",

journal = "Expert Opinion in Biological Therapy",

issn = "1471-2598",

publisher = "Taylor & Francis",

number = "8",

}

TY - JOUR

T1 - Ustekinumab

T2 - a novel therapeutic option in Crohn's disease

AU - Simon, E G

AU - Ghosh, Subrata

AU - Moran, G W

PY - 2016/8

Y1 - 2016/8

N2 - INTRODUCTION: Although anti-tumour necrosis factor (TNF) agents have caused a paradigm shift in the management of moderate-to-severe Crohn's, they are sometimes associated with diminished or absent response in a considerable proportion of patients. Hence agents targeting pathways other than TNF are needed. Ustekinumab is a monoclonal antibody directed against the p40 subunit of IL-12 and 23.AREAS COVERED: This manuscript summarises the available evidence on the efficacy and safety of Ustekinumab in Crohn's disease through data available from randomised controlled trials and compassionate use programs across the world.EXPERT OPINION: Current literature strongly supports the fact that ustekinumab is clinically efficacious and reasonably safe for induction and maintenance of remission in moderate-to-severe Crohn's disease.

AB - INTRODUCTION: Although anti-tumour necrosis factor (TNF) agents have caused a paradigm shift in the management of moderate-to-severe Crohn's, they are sometimes associated with diminished or absent response in a considerable proportion of patients. Hence agents targeting pathways other than TNF are needed. Ustekinumab is a monoclonal antibody directed against the p40 subunit of IL-12 and 23.AREAS COVERED: This manuscript summarises the available evidence on the efficacy and safety of Ustekinumab in Crohn's disease through data available from randomised controlled trials and compassionate use programs across the world.EXPERT OPINION: Current literature strongly supports the fact that ustekinumab is clinically efficacious and reasonably safe for induction and maintenance of remission in moderate-to-severe Crohn's disease.

KW - Journal Article

U2 - 10.1080/14712598.2016.1205582

DO - 10.1080/14712598.2016.1205582

M3 - Article

C2 - 27341173

SN - 1471-2598

VL - 16

SP - 1065

EP - 1074

JO - Expert Opinion in Biological Therapy

JF - Expert Opinion in Biological Therapy

IS - 8

ER -

Ustekinumab: a novel therapeutic option in Crohn's disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this